Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027

Cartesian Therapeutics, Inc.

Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.
R&D expenses rose to $58.0M from $45.1M, driven by Phase 3 AURORA trial and headcount growth.
Cash, equivalents and restricted cash of $126.9M expected to support operations into mid-2027, including AURORA completion.
Phase 3 AURORA trial for Descartes-08 in myasthenia gravis on track to enroll ~100 patients; Phase 2 TRITON in myositis IND accepted, initiation expected 1H26.
Board changes: Adrian Bot appointed in Dec 2025; Carsten Brunn named Chairman in Oct 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cartesian Therapeutics, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 9, 2026, Cartesian Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-26-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.